Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market Report 2026

Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market Overview

• Toll-Like Receptor 9 (TLR9) Agonist Adjuvants market size has reached to $2.04 billion in 2025 • Expected to grow to $2.99 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Surging Incidence Of Cancer Driving The Growth Of The Market Due To Rising Need For Immunotherapy-Based Cancer Treatments • Market Trend: Next-Generation Adjuvants Transform Shingles And Adult Vaccines, Offering Enhanced Immunogenicity And Tolerability • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market?

Toll-like receptor 9 (TLR9) agonist adjuvants are immunostimulatory agents that activate toll-like receptor 9, an intracellular pattern recognition receptor that detects unmethylated CpG motifs commonly found in microbial DNA. These agents mimic pathogen-associated molecular patterns and trigger innate immune signaling pathways, leading to increased cytokine production, enhanced antigen presentation, and activation of adaptive immune responses. The main types of Toll-Like Receptor 9 (TLR9) agonist adjuvants include synthetic cytosine phosphate guanine oligodeoxynucleotides (CpG ODN), natural immunostimulatory DNA, conjugated Toll-Like Receptor 9 agonists, and other formulation types. Synthetic cytosine phosphate guanine oligodeoxynucleotides (CpG ODN) are designed DNA sequences that stimulate the immune system by activating the Toll-Like Receptor 9 pathway, enhancing the effectiveness of vaccines and immunotherapies. The routes of administration include intratumoral, subcutaneous, intramuscular, intravenous, and rectal and the distribution channels include direct tender contracts, specialty distributors, online and e-commerce sales, and retail pharmacy channels. The various applications involved are cancer immunotherapy, infectious diseases, allergy treatment, and other applications, and are used by several end users such as pharmaceutical and biotechnology companies, contract research organizations, academic and research institutes, hospitals and diagnostic centers, and government and non-government health agencies.

What Is The Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market Growth Forecast?

The toll-like receptor 9 (TLR9) agonist adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.99 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to development of personalized cancer vaccines, integration of ai in immune response analysis, expansion of immunotherapy pipelines, demand for novel adjuvant delivery technologies, collaboration between pharma and biotech companies. Major trends in the forecast period include next-generation cpg odn formulations, personalized immunotherapy platforms, ai-enabled immune response monitoring, enhanced vaccine adjuvant delivery systems, integration with clinical data analytics.

Global Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market Segmentation

1) By Type: Synthetic Cytosine Phosphate Guanine Oligodeoxynucleotides (CpG ODN), Natural Immunostimulatory DNA, Conjugated Toll Like Receptor 9 Agonists, Other Formulation Types 2) By Route Of Administration: Intratumoral, Subcutaneous, Intramuscular, Intravenous, Rectal 3) By Distribution Channel: Direct Tender Contracts, Specialty Distributors, Online And E Commerce Sales, Retail Pharmacy Channel 4) By Application: Cancer Immunotherapy, Infectious Diseases, Allergy Treatment, Other Applications 5) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Hospitals And Diagnostic Centers, Government And Non Government Health Agencies Subsegments: 1) By Synthetic Cytosine Phosphate Guanine Oligodeoxynucleotides (CpG ODN): Class A Cytosine Phosphate Guanine Oligodeoxynucleotides (CpG ODN), Class B Cytosine Phosphate Guanine Oligodeoxynucleotides (CpG ODN), Class C Cytosine Phosphate Guanine Oligodeoxynucleotides (CpG ODN), Phosphorothioate Modified Cytosine Phosphate Guanine Oligodeoxynucleotides (CpG ODN), Nanoparticle Encapsulated Cytosine Phosphate Guanine Oligodeoxynucleotides (CpG ODN) 2) By Natural Immunostimulatory DNA: Bacterial Derived Immunostimulatory Deoxyribonucleic Acid (DNA), Viral Derived Immunostimulatory Deoxyribonucleic Acid (DNA), Plasmid Based Immunostimulatory Deoxyribonucleic Acid (DNA), Genomic Fragment Immunostimulatory Deoxyribonucleic Acid (DNA), Unmethylated Motif Rich Immunostimulatory Deoxyribonucleic Acid (DNA) 3) By Conjugated Toll Like Receptor 9 Agonists: Protein Conjugated Toll Like Receptor 9 Agonists (TLR9), Peptide Conjugated Toll Like Receptor 9 Agonists (TLR9), Nanoparticle Conjugated Toll Like Receptor 9 Agonists (TLR9), Antibody Linked Toll Like Receptor 9 Agonists (TLR9), Lipid Conjugated Toll Like Receptor 9 Agonists (TLR9) 4) By Other Formulation Types: Lyophilized Formulations, Liquid Suspension Formulations, Emulsion Based Formulations, Gel Based Formulations, Microsphere Encapsulated Formulations

What Is The Driver Of The Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market?

The surging incidence of cancer is expected to propel the growth of the toll like receptor 9 (TLR9) agonist adjuvants market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can invade tissues and organs. The incidence of cancer is rising due to aging populations, as older individuals have a higher risk of accumulating genetic mutations that can lead to cancer. TLR9 agonist adjuvants stimulate the immune system by activating toll-like receptor 9, enhancing the body’s ability to recognize and attack cancer cells, which improves the effectiveness of cancer therapies. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, over 35 million new cancer cases are predicted in 2050, a 77% increase from the 20 million cases in 2022. Therefore, the surging incidence of cancer is driving the growth of the toll‑like receptor 9 (TLR9) agonist adjuvants market.

Key Players In The Global Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market

Major companies operating in the toll-like receptor 9 (TLR9) agonist adjuvants market are GlaxoSmithKline plc, InvivoGen Inc., Idera Pharmaceuticals Inc., Creative Biolabs Inc.

Global Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market Trends and Insights

Major companies operating in the toll-like receptor 9 (TLR9) agonist adjuvants market are focusing on conducting clinical trials to develop innovative products, such as cytosine-phosphate-guanine (CpG) 1018-adjuvanted vaccines, to boost immune responses and improve vaccine efficacy. Cytosine-phosphate-guanine (CpG) 1018-adjuvanted vaccines are vaccines that include CpG 1018, a synthetic TLR9 (toll-Like receptor 9) agonist, which helps enhance the immune system by stimulating both antibody and T-cell responses for stronger and broader protection compared to traditional adjuvants. For instance, in October 2025, Dynavax Technologies Corporation, a US-based commercial-stage biopharmaceutical company, presented positive topline data for Z-1018, an investigational shingles vaccine formulated with CpG 1018, a TLR9 agonist adjuvant. It is a non-live, recombinant subunit vaccine combining glycoprotein E with CpG 1018 and alum, designed to overcome age-related decline in immune response. The vaccine demonstrated strong anti-gE IgG antibody responses, robust polyfunctional CD4+ T-cell activation, and favorable tolerability in adults aged 50–69, with Part 2 of the Phase 1/2 trial now underway in adults aged 70 and older to confirm efficacy and safety head-to-head against Shingrix. This product highlights the shift toward adjuvants that not only enhance antibody titers but also broaden cellular immunity, providing a differentiated alternative to conventional vaccines.

What Are Latest Mergers And Acquisitions In The Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market?

In February 2026, Sanofi S.A., a France-based pharmaceutical company, acquired Dynavax Technologies Corporation for an undisclosed amount. With this acquisition, Sanofi S.A. aims to strengthen its adult immunization portfolio by integrating Dynavax Technologies Corporation’s vaccines with its global commercial reach and development capabilities. Dynavax Technologies Corporation is a US-based biotech company that specializes in providing TLR9 agonist adjuvants.

Regional Insights

North America was the largest region in the toll-like receptor 9 (TLR9) agonist adjuvants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market?

The toll-like receptor 9 (TLR9) agonist adjuvants market consists of sales of cytosine-phosphate-guanine (CpG) oligodeoxynucleotides, cytosine-phosphate-guanine (CpG)-containing plasmid DNA constructs, formulated TLR9-stimulating adjuvant systems, and CpG motif–containing immunostimulatory agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Toll-Like Receptor 9 (TLR9) Agonist Adjuvants Market Report 2026?

The toll-like receptor 9 (tlr9) agonist adjuvants market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the toll-like receptor 9 (tlr9) agonist adjuvants industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.